IFNA1 and COVID-19: Two reports characterized the BALF immune signatures from COVID-19 patients using scRNA-seq or RNA-seq during the initial stages of the COVID-19 pandemic and revealed the disruption of bronchoalveolar epithelial barriers, extensive immune infiltration, hypercytokinemia, and an increase in IFN-induced responses [32, 80].